GSK-LSD1
Based on 14 publication(s) in Google Scholar
GSK-LSD1, a chemical probe, is a LSD1 inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 1431368-48-7
- 화학식: C14H20N2
- 분자량:216.32
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) GSK-LSD1
More- Signal Transduct Target Ther. 2022 Apr 13;7(1):102. [Abstract]
- Nature. 2025 Jun;642(8067):508-518. [Abstract]
- Adv Mater. 2021 May;33(18):e2100949. [Abstract]
- Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]
- Nat Commun. 2025 Jan 2;16(1):212. [Abstract]
- Nat Commun. 2021 Dec 8;12(1):7142. [Abstract]
- Bioorg Chem. 2024 Sep:150:107603. [Abstract]
- Sci Rep. 2026 Mar 2;16(1):8917. [Abstract]
- Clin Exp Med. 2025 Nov 25;26(1):33. [Abstract]
- Cytokine. 2022 Mar:151:155789. [Abstract]
- Amino Acids. 2026 May 19. [Abstract]
- Res Sq. 2025 Apr 01.
- bioRxiv. 2024 Aug 19:2024.08.17.607802. [Abstract]
- Patent. US20180263995A1.
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Cell Imaging/Staining
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
>64 μM
Compound: GSK-LSD1
|
Antiproliferative activity against human HCT-116 cells incubated for 48 hrs measured by MTT assay
Antiproliferative activity against human HCT-116 cells incubated for 48 hrs measured by MTT assay
|
[PMID: 36881982] |
| KYSE-450 | IC50 |
>64 μM
Compound: GSK-LSD1
|
Antiproliferative activity against human KYSE-450 cells incubated for 48 hrs measured by MTT assay
Antiproliferative activity against human KYSE-450 cells incubated for 48 hrs measured by MTT assay
|
[PMID: 36881982] |
| MGC-803 | IC50 |
>64 μM
Compound: GSK-LSD1
|
Antiproliferative activity against human MGC-803 cells incubated for 48 hrs measured by MTT assay
Antiproliferative activity against human MGC-803 cells incubated for 48 hrs measured by MTT assay
|
[PMID: 36881982] |
Chemical Information
-
CAS No. 1431368-48-7
-
분자량 216.32
-
화학식 C14H20N2
-
SMILES
C1(N[C@H]2[C@H](C3=CC=CC=C3)C2)CCNCC1
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (14)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
2022 Apr 13;7(1):102. PMID: 35414135
GSK-LSD1 purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2022 Apr 13;7(1):102. [Abstract]
Comparison of genome-wide replication timing after LSD1 was depleted or inhibited. HeLa cells were transfected with LSD1 siRNAs or treated with GSK-LSD1 dihydrochloride prior to synchronization in early S phase for Repli-seq. The results from a representative region of chromosome 2 spanning 49 Mb are illustrated. Regions with decreased Repli-seq reads density after LSD1 depletion/inhibition are shaded in pink, and regions with increased reads density shaded in gray. Replication profiles from public data representing early (G1b) and late (G2) S phases and the distribution of H3K4me2 and H3K27ac are shown. Numbers in square brackets indicate the data range of corresponding track. Statistical analysis of Repli-seq reads density around the summits of LSD1 binding sites is shown (right panel).
GSK-LSD1 purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2022 Apr 13;7(1):102. [Abstract]
Statistical analysis of the Repli-seq results showed that the reads density around LSD1 summits decreased in LSD1 knockdown and GSK-LSD1 dihydrochloride groups.
-
Nature
Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation. [Abstract]2025 Jun;642(8067):508-518. PMID: 40240608
GSK-LSD1 purchased from MedChemExpress. Usage Cited in: Nature. 2025 Jun;642(8067):508-518. [Abstract]
PCA of RNA-seq of THP-1 cells treated with vehicle, GSK-LSD1 dihydrochloride, LY2090314 or combination of both inhibitors.
GSK-LSD1 purchased from MedChemExpress. Usage Cited in: Nature. 2025 Jun;642(8067):508-518. [Abstract]
Quantification of colonies formed by a NPM1-mutant primary AML sample treated with DMSO, GSK-LSD1 dihydrochloride (50 nM, 7-10 days), LY2090314 (100 nM) or combination of both inhibitors.
GSK-LSD1 purchased from MedChemExpress. Usage Cited in: Nature. 2025 Jun;642(8067):508-518. [Abstract]
Wright-Giemsa-stained cytospins for primary AML samples treated with DMSO, GSK-LSD1 dihydrochloride (50 nM), LY2090314 (100 nM) and combination of both inhibitors.
-
Adv Mater
Epigenetic Remodeling Hydrogel Patches for Multidrug-Resistant Triple-Negative Breast Cancer. [Abstract]2021 May;33(18):e2100949. PMID: 33792093 -
Nat Commun
Copy number amplification of FLAD1 promotes the progression of triple-negative breast cancer through lipid metabolism. [Abstract]2025 Feb 1;16(1):1241. PMID: 39890808 -
Nat Commun
Mitochondrial-cytochrome c oxidase II promotes glutaminolysis to sustain tumor cell survival upon glucose deprivation. [Abstract]2025 Jan 2;16(1):212. PMID: 39747079 -
Nat Commun
Growth differentiation factor 1-induced tumour plasticity provides a therapeutic window for immunotherapy in hepatocellular carcinoma. [Abstract]2021 Dec 8;12(1):7142. PMID: 34880251 -
Bioorg Chem
Discovery of TCP-(MP)-caffeic acid analogs as a new class of agents for treatment of osteoclastic bone loss. [Abstract]2024 Sep:150:107603. PMID: 38968905 -
Sci Rep
Discovery of natural apigenin analogues as lysine-specific demethylase 1 inhibitors against tumoral testicular germ cells. [Abstract]2026 Mar 2;16(1):8917. PMID: 41772063 -
Clin Exp Med
Corin: a dual inhibitor for KDM1A/HDAC1, suppresses hepatocellular carcinoma by triggering cuproptosis. [Abstract]2025 Nov 25;26(1):33. PMID: 41286164 -
Cytokine
2022 Mar:151:155789. PMID: 34998158 -
Amino Acids
2026 May 19. PMID: 42156569 -
-
bioRxiv
The CoREST complex is a therapeutic vulnerability in malignant peripheral nerve sheath tumors. [Abstract]2024 Aug 19:2024.08.17.607802. PMID: 39229179 -
순도&문서
References
[1]. Ramms B, et al. Systemic LSD1 Inhibition Prevents Aberrant Remodeling of Metabolism in Obesity. Diabetes. 2022 Dec 1;71(12):2513-2529. [Content Brief]
[2]. Hong KS, et al. GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro. Signal Transduct Target Ther. 2020 Nov 17;5(1):267. [Content Brief]
[3]. Alsaqer SF, et al. Inhibition of LSD1 epigenetically attenuates oral cancer growth and metastasis. Oncotarget. 2017 Jul 27;8(43):73372-73386. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
GSK-LSD1 Related Classifications
HY-100546 Related Classifications
Powered by Bioz